0RU5

Bergenbio Asa (0RU5)

Bergenbio Asa

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:LSE:0RU5

1 2 3 4 5 6 7 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2023/08/22	17:50	PR Newswire (US)	BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer	LSE:0RU5	Bergenbio Asa
2023/08/22	17:45	PR Newswire (US)	BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer	LSE:0RU5	Bergenbio Asa
2023/05/26	22:07	PR Newswire (US)	BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue	LSE:0RU5	Bergenbio Asa
2023/04/26	01:26	PR Newswire (US)	BerGenBio ASA: Proposed partially underwritten rights issue	LSE:0RU5	Bergenbio Asa
2023/04/18	14:23	PR Newswire (US)	BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR	LSE:0RU5	Bergenbio Asa
2023/04/18	14:20	PR Newswire (US)	BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR	LSE:0RU5	Bergenbio Asa
2023/03/09	19:22	PR Newswire (US)	BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations	LSE:0RU5	Bergenbio Asa
2023/03/09	19:20	PR Newswire (US)	BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations	LSE:0RU5	Bergenbio Asa
2023/02/16	15:32	PR Newswire (US)	BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update	LSE:0RU5	Bergenbio Asa
2023/02/16	15:30	PR Newswire (US)	BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update	LSE:0RU5	Bergenbio Asa
2023/02/16	01:35	PR Newswire (US)	BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients	LSE:0RU5	Bergenbio Asa
2023/02/16	01:31	PR Newswire (US)	BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients	LSE:0RU5	Bergenbio Asa
2023/02/02	15:17	PR Newswire (US)	BerGenBio Announces the Establishment of Oncology Scientific Advisory Board	LSE:0RU5	Bergenbio Asa
2023/02/02	15:15	PR Newswire (US)	BerGenBio Announces the Establishment of Oncology Scientific Advisory Board	LSE:0RU5	Bergenbio Asa
2022/11/15	15:10	PR Newswire (US)	BerGenBio reports third quarter 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
2022/11/15	15:07	PR Newswire (US)	BerGenBio reports third quarter 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
2022/10/25	14:37	PR Newswire (US)	BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS	LSE:0RU5	Bergenbio Asa
2022/10/25	14:34	PR Newswire (US)	BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS	LSE:0RU5	Bergenbio Asa
2022/10/11	14:36	PR Newswire (US)	BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations	LSE:0RU5	Bergenbio Asa
2022/10/11	14:34	PR Newswire (US)	BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations	LSE:0RU5	Bergenbio Asa
2022/09/27	22:31	PR Newswire (US)	BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS	LSE:0RU5	Bergenbio Asa
2022/09/27	22:28	PR Newswire (US)	BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS	LSE:0RU5	Bergenbio Asa
2022/08/23	14:36	PR Newswire (US)	BerGenBio reports second quarter and half year 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
2022/08/23	14:34	PR Newswire (US)	BerGenBio reports second quarter and half year 2022 financial results and provides business update	LSE:0RU5	Bergenbio Asa
2022/05/04	14:29	PR Newswire (US)	BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19	LSE:0RU5	Bergenbio Asa
2022/05/04	14:27	PR Newswire (US)	BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19	LSE:0RU5	Bergenbio Asa
2022/04/26	14:13	PR Newswire (US)	BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET	LSE:0RU5	Bergenbio Asa
2022/04/26	14:12	PR Newswire (US)	BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET	LSE:0RU5	Bergenbio Asa
2022/04/11	14:12	PR Newswire (US)	BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer	LSE:0RU5	Bergenbio Asa
2022/04/07	21:20	PR Newswire (US)	BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021	LSE:0RU5	Bergenbio Asa